P2RY12 and chronic kidney disease: A previous meta-analysis (28) investigating potent P2Y12 inhibitors compared to clopidogrel in patients with ACS combined with CKD pointed out that potent P2Y12 inhibitors lead to a reduction in the incidence of MACE without an increase in the rate of major bleeding.